StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $9.76 | $9.78 | +0.20% | 0.0M |
| 05-12 | $9.86 | $9.78 | -0.81% | 0.0M |
| 05-13 | $9.78 | $9.80 | +0.26% | 0.0M |
| 05-14 | $9.96 | $10.25 | +2.91% | 0.0M |
| 05-15 | $9.89 | $9.74 | -1.57% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2020 2020-12-31 | Q3 2020 2020-09-30 | Q2 2020 2020-06-30 | Q1 2020 2020-03-31 |
|---|---|---|---|---|
Revenue | $22.38M | $22.38M | $22.38M | $22.38M |
Operating Income | $-41.23M | $-24.99M | $-7.59M | $8.21M |
Net Income | $-36.60M | $-21.14M | $-14.51M | $9.73M |
EPS (Diluted) | $-1.33 | $-0.77 | Not available | $0.33 |
Total Assets | $306.64M | $316.08M | $333.49M | $343.47M |
Total Liabilities | $12.92M | $8.74M | $11.57M | $11.71M |
Cash & Equivalents | $32.77M | $22.53M | $25.05M | $28.91M |
Free Cash Flow OCF − CapEx | $-52.09M | $-44.83M | $-27.28M | $-12.04M |
Shares Outstanding | 27.57M | 27.55M | 27.52M | 27.52M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.